β1-Adrenergic antagonist monotherapy of male rabbits with ischemic HFrEF reverses sarcolemmal Na + -K + pump inhibition and reduces lung congestion
American Journal of Physiology-Cell Physiology · 2026
DOI: 10.1152/ajpcell.00177.2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2026. Verfasst von Natasha A S Fry und 7 weiteren Autor:innen. Beteiligte Einrichtung: North Shore Heart Research Group, Kolling Medical Research Institute, University of Sydney, St Leonards, New South Wales, Australia. Hauptthemen laut MEDLINE: Sodium-Potassium-Exchanging ATPase, Heart Failure, Adrenergic beta-1 Receptor Antagonists, Metoprolol. Die Arbeit nennt 50 Literaturangaben. Gefördert von: AstraZeneca Australia, National Heart Foundation of Australia (Heart Foundation), Heart Research Australia (HRA).
Abstract (Originalsprache)
β1AR antagonists are frequently the only guideline-directed treatment tolerated in heart failure with reduced ejection fraction (HFrEF), and they might be deleterious because raised cytosolic [Na + ] is harmful in HFrEF and β1AR agonists reportedly enhance myocyte Na + export. Here, an antagonist reversed reduced Na + -K + pump function of myocytes from noninfarcted myocardium in an ischemic model of HFrEF and improved pulmonary congestion, consistent with benefit of Na + export but not with widely reported β1AR agonist-induced export.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- North Shore Heart Research Group, Kolling Medical Research Institute, University of Sydney, St Leonards, New South Wales, Australia.
- Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Department of Cardiology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
ORCID-Profile: Chia-Chi Liu, Elisha J Hamilton, Helge H Rasmussen
Förderung
- AstraZeneca Australia
- National Heart Foundation of Australia (Heart Foundation)
- Heart Research Australia (HRA)
- DHAC | National Health and Medical Research Council (NHMRC)
- Beryl Raymer Trust
Zitieren
APA
Fry, N. A. S., Liu, C. C., Garcia, A., Hamilton, E. J., Kim, Y. J., Karimi Galougahi, K., Bundgaard, H., & Rasmussen, H. H. (2026). β1-Adrenergic antagonist monotherapy of male rabbits with ischemic HFrEF reverses sarcolemmal Na + -K + pump inhibition and reduces lung congestion. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00177.2026
Vancouver
Fry NAS, Liu CC, Garcia A, Hamilton EJ, Kim YJ, Karimi Galougahi K, et al. β1-Adrenergic antagonist monotherapy of male rabbits with ischemic HFrEF reverses sarcolemmal Na + -K + pump inhibition and reduces lung congestion. American Journal of Physiology-Cell Physiology. 2026. doi:10.1152/ajpcell.00177.2026
BibTeX
@article{Fry2026,
author = {Fry, Natasha A S and Liu, Chia-Chi and Garcia, Alvaro and Hamilton, Elisha J and Kim, Yeon Jae and Karimi Galougahi, Keyvan and Bundgaard, Henning and Rasmussen, Helge H},
title = {β1-Adrenergic antagonist monotherapy of male rabbits with ischemic HFrEF reverses sarcolemmal Na + -K + pump inhibition and reduces lung congestion},
journal = {American Journal of Physiology-Cell Physiology},
year = {2026},
doi = {10.1152/ajpcell.00177.2026}
}
EUVIMED